常州千红生化制药股份有限公司 2017 年第一季度报告正文 证券代码：002550 证券简称：千红制药 公告编号：2017-026 常州千红生化制药股份有限公司 2017 年第一季度报告正文 证券简称：千红制药 证券代码：002550 2017 年 04 月 25 日 1 常州千红生化制药股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王耀方、主管会计工作负责人肖爱群及会计机构负责人(会计主 管人员)肖爱群声明：保证季度报告中财务报表的真实、准确、完整。 2 常州千红生化制药股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 243,708,343.81 | 156,701,933.57 | 55.52% | | 归属于上市公司股东的净利 ...

常州千红生化制药股份有限公司 2016 年年度报告全文 常州千红生化制药股份有限公司 2016 年年度报告 证券简称：千红制药 证券代码：002550 2017 年 04 月 25 日 1 常州千红生化制药股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人王耀方、主管会计工作负责人肖爱群及会计机构负责人(会计主 管人员)肖爱群声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能存在药品招标风险，外部经济环境的不确定性风险、产品质量风 险、产品销售价格波动的风险、经营成本增加的风险、行业竞争加剧的风险、 汇率波动的风险等。 公司经本次董事会审议通过的利润分配预案为：以 1,273,721 ,200 为基数， 向全体股东每 10 股派发现金红利 0.80 元（含税），送红股 0 股（含税），不以公 积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | -- ...

常州千红生化制药股份有限公司 2016 年第三季度报告正文 证券代码：002550 证券简称：千红制药 公告编号：2016-036 常州千红生化制药股份有限公司 常州市新北区长江中路 90 号 千红制药 二 O 一六年第三季度报告正文 股票简称：千红制药 股票代码：002550 披露时间：2016 年 10 月 22 日 1 常州千红生化制药股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王耀方、主管会计工作负责人赵刚及会计机构负责人(会计主管 人员)肖爱群声明：保证季度报告中财务报表的真实、准确、完整。 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,864,760,823.11 | 2,833,137,726.31 | | 1.12% | | 归属于上市公司股东的净资产 | ...

[Important Notes, Table of Contents and Definitions](index=2&type=section&id=Item%20I.%20Important%20Notes%2C%20Table%20of%20Contents%20and%20Definitions) This section provides essential disclaimers, the report's table of contents, and key definitions for clarity - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the first half of 2016[3](index=3&type=chunk)[5](index=5&type=chunk) [Company Profile](index=5&type=section&id=Item%20II.%20Company%20Profile) This section provides fundamental information about the company, including its registration details and contact channels [Company Overview](index=5&type=section&id=I.%20Company%20Overview) This chapter provides the company's basic business registration information, including stock abbreviation "Qianhong Pharma", stock code "002550", and the company's full Chinese and English names and legal representative Company Basic Information | Item | Content | | :--- | :--- | | Stock Abbreviation | Qianhong Pharma | | Stock Code | 002550 | | Stock Exchange | Shenzhen Stock Exchange | | Chinese Name | Changzhou Qianhong Bio-pharma Co., Ltd. | | Legal Representative | Wang Yaofang | [Contact Person and Information](index=5&type=section&id=II.%20Contact%20Person%20and%20Information) This chapter discloses the name and contact information of the company's board secretary, serving as the primary external communication channel Board Secretary Contact Information | Position | Name | Phone | Email | | :--- | :--- | :--- | :--- | | Board Secretary | Jiang Wenqun | 0519-85156003 | stock@qhsh.com.cn | [Other Information](index=5&type=section&id=III.%20Other%20Information) This chapter describes the company's information disclosure media and registration changes. During the reporting period, the company's designated information disclosure newspapers were "Securities Times" and "Shanghai Securities News", and it completed the "three-in-one" change for business registration information - The company's designated information disclosure newspapers are "Securities Times" and "Shanghai Securities News", and the designated website is Juchao Information Network (http://www.cninfo.com.cn)[16](index=16&type=chunk) - During the reporting period, the company completed the "three-in-one" change for business registration information, unifying the new registration number, tax registration number, and organization code to 91320400748726864T[17](index=17&type=chunk) [Summary of Accounting Data and Financial Indicators](index=7&type=section&id=Item%20III.%20Summary%20of%20Accounting%20Data%20and%20Financial%20Indicators) This section presents a concise overview of the company's key financial performance and position during the reporting period [Key Accounting Data and Financial Indicators](index=7&type=section&id=I.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company achieved operating revenue of **362 million CNY**, a year-on-year increase of **9.50%**; net profit attributable to shareholders of listed company was **143 million CNY**, a year-on-year increase of **7.29%**. Net cash flow from operating activities decreased by **8.12%** year-on-year Key Financial Data for H1 2016 | Indicator | Current Period (CNY) | Prior Year Period (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 362,339,737.55 | 330,909,032.54 | 9.50% | | Net Profit Attributable to Shareholders of Listed Company | 142,851,942.06 | 133,143,671.57 | 7.29% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Gains/Losses) | 95,428,731.50 | 94,296,433.99 | 1.20% | | Net Cash Flow from Operating Activities | 160,916,492.13 | 175,139,448.67 | -8.12% | | Basic Earnings Per Share (CNY/share) | 0.1116 | 0.1040 | 7.31% | | Weighted Average Return on Net Assets | 6.13% | 6.15% | -0.02% | | Total Assets (CNY) | 2,845,714,250.45 | 2,833,137,726.31 | 0.44% | | Net Assets Attributable to Shareholders of Listed Company (CNY) | 2,321,038,424.02 | 2,274,186,481.96 | 2.06% | [Non-recurring Gains and Losses Items and Amounts](index=7&type=section&id=III.%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to **47.42 million CNY**. The main contribution came from wealth management income from bank wealth management products and trust products, totaling **55.96 million CNY** Non-recurring Gains and Losses Items | Item | Amount (CNY) | Explanation | | :--- | :--- | :--- | | Other gains and losses items conforming to the definition of non-recurring gains and losses | 55,959,790.90 | Includes income from bank wealth management products and trust products | | Government grants recognized in current profit or loss | 686,796.43 | - | | Gains or losses on disposal of non-current assets | -434,837.41 | - | | Less: Income tax impact | 8,525,308.06 | - | | Less: Impact of minority interests (after tax) | 273,930.15 | - | | **Total** | **47,423,210.56** | **--** | [Board of Directors' Report](index=9&type=section&id=Item%20IV.%20Board%20of%20Directors'%20Report) This section outlines the company's operational performance and strategic initiatives during the reporting period [Business Overview](index=9&type=section&id=I.%20Business%20Overview) During the reporting period, facing pressure from drug tender price reductions, the company maintained stable and healthy economic development by expanding markets, enriching product structure, improving R&D platforms, and advancing fundraising projects. Key initiatives included acquiring Innosenkang to fill the gap in small molecule drug R&D and new plant construction passing new GMP acceptance - The company maintained continuous, stable, and healthy economic development by expanding sales markets for key products and mitigating the downward pressure on drug tender prices[28](index=28&type=chunk) - The company obtained approval for enoxaparin sodium and dalteparin sodium APIs and preparations, enriching its product structure and creating new economic growth points. Enoxaparin sodium injection has been launched and is generating sales[28](index=28&type=chunk) - The company completed the acquisition of **55%** equity in Changzhou Innosenkang Biomedical Technology Co., Ltd., filling the technical gap in small molecule drug R&D and complementing the existing large molecule R&D platform[29](index=29&type=chunk) - The company's new plant construction project in Changzhou Biomedical Industrial Park fully passed new GMP acceptance, and fundraising projects are largely complete, providing assurance for industrial transformation and upgrading[30](index=30&type=chunk) [Analysis of Main Business](index=10&type=section&id=II.%20Analysis%20of%20Main%20Business) During the reporting period, the company's operating revenue increased by **9.50%**, mainly due to higher API sales; operating costs rose by **17.74%** due to increased product sales and raw material prices. Financial expenses decreased by **24.71%** due to increased wealth management income. Net cash flow from operating activities decreased by **8.12%**, primarily due to the return of some project deposits Key Financial Data YoY Changes | Item | Current Period (CNY) | Prior Year Period (CNY) | YoY Change | Main Reason | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 362,339,737.55 | 330,909,032.54 | 9.50% | Increased API sales | | Operating Cost | 133,814,908.24 | 113,651,169.02 | 17.74% | Increased product sales and raw material prices | | Financial Expenses | -53,279,145.83 | -42,721,270.54 | -24.71% | Increased wealth management income | | Net Cash Flow from Operating Activities | 160,916,492.13 | 175,139,448.67 | -8.12% | Return of some project deposits | | Net Cash Flow from Investing Activities | -66,846,282.54 | -218,372,770.22 | 69.39% | Maturity of some wealth management products | | Net Cash Flow from Financing Activities | -61,389,883.63 | 96,123,165.97 | -163.87% | Repayment of some bank loans | [Main Business Composition](index=11&type=section&id=III.%20Main%20Business%20Composition) The company's main business is biopharmaceuticals, with a gross profit margin of **63.14%**, a year-on-year decrease of **2.60%**. By product, API series revenue grew by **24.97%**, while pharmaceutical preparations series only grew by **0.67%**. By region, international revenue grew by **22.27%**, significantly higher than the **4.08%** growth in domestic regions Main Business Composition | Category | Operating Revenue (CNY) | Operating Cost (CNY) | Gross Profit Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Profit Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **By Product** | | | | | | | | API Series | 150,351,496.44 | 95,315,881.94 | 36.60% | 24.97% | 27.43% | -1.22% | | Pharmaceutical Preparations Series | 211,390,936.91 | 38,039,090.77 | 82.01% | 0.67% | 0.30% | 0.07% | | **By Region** | | | | | | | | Domestic Region | 241,229,340.13 | 54,987,774.03 | 77.21% | 4.08% | 10.80% | -1.38% | | International Region | 120,513,093.22 | 78,367,198.68 | 34.97% | 22.27% | 23.30% | -0.54% | [Analysis of Core Competencies](index=11&type=section&id=IV.%20Analysis%20of%20Core%20Competencies) During the reporting period, the company's core competencies did not undergo significant changes compared to the annual report - The company's core competencies did not undergo significant changes during the reporting period[37](index=37&type=chunk) [Analysis of Investment Status](index=12&type=section&id=V.%20Analysis%20of%20Investment%20Status) During this reporting period, the company made significant external equity investments, acquiring **55%** of Changzhou Innosenkang Biomedical Technology Co., Ltd. for **16.5 million CNY**. Concurrently, the company actively utilized idle self-owned and raised funds for entrusted wealth management, involving substantial amounts. The use of raised funds also progressed as planned, primarily for capacity expansion and R&D center construction [External Equity Investments](index=12&type=section&id=1.%20External%20Equity%20Investments) During the reporting period, the company's external investment amounted to **16.5 million CNY**, used to acquire **55%** equity in Changzhou Innosenkang Biomedical Technology Co., Ltd. to strengthen its biopharmaceutical R&D capabilities External Investment Details | Investee Company Name | Main Business | Investment Amount (CNY) | Equity Ratio in Investee Company | | :--- | :--- | :--- | :--- | | Changzhou Innosenkang Biomedical Technology Co., Ltd. | R&D of biopharmaceuticals, technical services, technical consulting, and technology transfer | 16,500,000.00 | 55.00% | [Entrusted Wealth Management, Derivative Investments, and Entrusted Loans](index=12&type=section&id=2.%20Entrusted%20Wealth%20Management%2C%20Derivative%20Investments%2C%20and%20Entrusted%20Loans) The company utilized idle self-owned funds and raised funds for large-scale entrusted wealth management, primarily investing in trust products and bank principal-protected wealth management products, totaling **1.49 billion CNY**, with a realized profit of **33.18 million CNY** during the reporting period - The company used idle self-owned funds and raised funds for entrusted wealth management, totaling **1.48992 billion CNY**, with actual profit/loss of **33.1768 million CNY** during the reporting period[44](index=44&type=chunk) - Entrusted wealth management funds originated from the company's idle self-owned funds and raised funds, of which **269.92 million CNY** were raised funds[44](index=44&type=chunk) [Use of Raised Funds](index=14&type=section&id=3.%20Use%20of%20Raised%20Funds) As of the end of the reporting period, the company's total raised funds amounted to **1.215 billion CNY**, with cumulative investment of **1.097 billion CNY**, accounting for **90.3%** of the total. Funds were primarily used for expansion projects of heparin, kallidinogenase, etc., joint research institute construction, and supplementing working capital. Some projects were delayed until March 31, 2016, due to changes in implementation locations, and are now largely complete Overall Use of Raised Funds (CNY 10,000) | Item | Amount | | :--- | :--- | | Total Raised Funds | 121,481.91 | | Total Raised Funds Invested in Current Period | 27,870.82 | | Total Raised Funds Cumulatively Invested | 109,744.42 | | Total Raised Funds with Changed Purpose (Cumulative) | 13,683 | | Proportion of Total Raised Funds with Changed Purpose (Cumulative) | 11.26% | - As of June 30, 2016, the company cumulatively used **1.097 billion CNY** in raised funds, including **727 million CNY** invested in fundraising projects, **20 million CNY** for acquiring Innosenkang equity, **232 million CNY** for repaying bank loans, and **119 million CNY** for permanently supplementing working capital[51](index=51&type=chunk) - The completion deadline for the pharmaceutical preparation parts of multiple fundraising projects was adjusted from September 30, 2015, to March 31, 2016, due to changes in implementation locations. As of the end of the reporting period, the pharmaceutical preparation varieties in the new plant area have obtained GMP certificates, and five fundraising projects are largely complete[55](index=55&type=chunk) [Analysis of Major Subsidiaries and Associates](index=19&type=section&id=4.%20Analysis%20of%20Major%20Subsidiaries%20and%20Associates) During the reporting period, the company's major subsidiaries were mostly in the investment or development stage and had not yet achieved profitability. Among them, Jiangsu Zhonghong Bioengineering Innovation Research Institute Co., Ltd. had a net loss of **0.57 million CNY**, Hubei Runhong Biotechnology Co., Ltd. had a net loss of **1.74 million CNY**, and the newly acquired Changzhou Innosenkang Biomedical Technology Co., Ltd. had a net loss of **2.51 million CNY** Major Subsidiary Financial Performance (CNY) | Company Name | Operating Revenue | Operating Profit | Net Profit | | :--- | :--- | :--- | :--- | | Jiangsu Zhonghong Bioengineering Innovation Research Institute Co., Ltd. | 6,451,497.33 | -587,251.75 | -566,715.12 | | Jiangsu Jinghong Biomedical Technology Co., Ltd. | 0.00 | -408,470.69 | -408,470.69 | | Hubei Runhong Biotechnology Co., Ltd. | 0.00 | -1,496,767.33 | -1,744,580.19 | | Changzhou Innosenkang Biomedical Technology Co., Ltd. | 4,680.38 | -2,478,345.20 | -2,506,845.20 | [Forecast of Operating Performance for January-September 2016](index=21&type=section&id=VI.%20Forecast%20of%20Operating%20Performance%20for%20January-September%202016) The company expects the net profit attributable to shareholders of the listed company for January-September 2016 to fluctuate between **-20%** and **20%**. The main reasons for performance fluctuations include increased market investment due to new product promotion and potential temporary sales decline of the core product "Yikai" due to specification changes in some markets 2016 Q1-Q3 Performance Forecast | Item | Content | | :--- | :--- | | Net Profit Fluctuation Range | -20.00% to 20.00% | | Net Profit Fluctuation Range (CNY 10,000) | 16,106.46 to 24,159.68 | | Net Profit for Prior Year Period (CNY 10,000) | 20,133.07 | | Reasons for Performance Change | 1. Increased market investment for promoting new products like enoxaparin sodium injection;<br>2. Temporary sales decline of Yikai in some important markets due to specification changes;<br>3. Expected sales growth for other products. | [Implementation of Profit Distribution Plan for the Reporting Period](index=21&type=section&id=IX.%20Implementation%20of%20Profit%20Distribution%20Plan%20for%20the%20Reporting%20Period) The company implemented its 2015 annual profit distribution plan, distributing a cash dividend of **CNY 1.5** (tax inclusive) per **10 shares** based on a total share capital of **640 million shares**, totaling **96 million CNY** in cash. Concurrently, **10 bonus shares** were issued per **10 shares** from capital reserves, increasing the total share capital to **1.28 billion shares**. The plan was completed on May 24, 2016 - 2015 annual profit distribution plan: **CNY 1.5** cash dividend (tax inclusive) per **10 shares**, and **10 bonus shares** per **10 shares** from capital reserves[69](index=69&type=chunk) - After distribution, the company's total share capital increased from **640 million shares** to **1.28 billion shares**, and the distribution plan was completed on May 24, 2016[69](index=69&type=chunk)[70](index=70&type=chunk) [Proposed Profit Distribution or Capital Reserve to Share Capital Conversion Plan for the Reporting Period](index=22&type=section&id=X.%20Proposed%20Profit%20Distribution%20or%20Capital%20Reserve%20to%20Share%20Capital%20Conversion%20Plan%20for%20the%20Reporting%20Period) The company plans not to distribute profits for the first half of 2016, meaning no cash dividends, no bonus shares, and no conversion of capital reserves into share capital - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year period[72](index=72&type=chunk) [Significant Matters](index=23&type=section&id=Item%20V.%20Significant%20Matters) This section details significant events and transactions that occurred during the reporting period [Asset Transactions](index=23&type=section&id=V.%20Asset%20Transactions) During the reporting period, the company acquired **55%** equity in Changzhou Innosenkang Biomedical Technology Co., Ltd. for **16.5 million CNY**. This acquisition aims to enhance the company's small molecule chemical drug innovation R&D platform, complementing the large molecule R&D platform of its subsidiary Zhonghong Research Institute, thereby improving overall R&D capabilities Acquisition of Assets | Acquired Asset | Transaction Price (CNY 10,000) | Progress | Impact on Company Operations | | :--- | :--- | :--- | :--- | | 55% Innosenkang Equity | 1,650 | Asset ownership has been fully transferred | Enhances the company's small molecule chemical drug innovation R&D platform, complementing and promoting the large molecule R&D platform. | [Commitments Made by the Company or Shareholders Holding 5% or More of Shares During or Prior to the Reporting Period and Continuing into the Reporting Period](index=26&type=section&id=IX.%20Commitments%20Made%20by%20the%20Company%20or%20Shareholders%20Holding%205%25%20or%20More%20of%20Shares%20During%20or%20Prior%20to%20the%20Reporting%20Period%20and%20Continuing%20into%20the%20Reporting%20Period) The company's controlling shareholder Wang Yaofang and shareholders holding **5%** or more, such as Zhao Gang, are fulfilling their commitments to avoid horizontal competition made during the initial public offering. Additionally, Wang Yaofang and Zhao Gang committed to an additional **3-year** lock-up period for part of their shares, extending until February 24, 2017 - Controlling shareholder Wang Yaofang and Zhao Gang committed not to directly or indirectly engage in any business that constitutes horizontal competition with the company; this commitment is permanent and is currently being fulfilled normally[95](index=95&type=chunk) - Wang Yaofang and Zhao Gang separately committed to an additional **3-year** lock-up period for **230 million shares** and **102 million shares** respectively, with the lock-up period extending until February 24, 2017; these commitments are currently being fulfilled normally[95](index=95&type=chunk)[96](index=96&type=chunk) [Explanation of Other Significant Matters](index=27&type=section&id=XII.%20Explanation%20of%20Other%20Significant%20Matters) During the reporting period, the company made several significant advancements: completing the acquisition of **55%** equity in Innosenkang and planning to acquire an additional **10%**; obtaining drug registration approvals for dalteparin sodium and its injection; and securing GMP certificates for enoxaparin API and various preparations (including tablets, capsules, etc.), providing assurance for expanding production scale - Completed the acquisition of **55%** equity in Changzhou Innosenkang and plans to continue acquiring the remaining **10%** state-owned equity to fill the gap in small molecule drug R&D[99](index=99&type=chunk) - Obtained drug registration approvals for dalteparin sodium and its injection[99](index=99&type=chunk) - Obtained GMP certificates for enoxaparin API, small volume injections, lyophilized powder injections, tablets, hard capsules, and other dosage forms, providing assurance for expanding production[99](index=99&type=chunk) [Share Changes and Shareholder Information](index=28&type=section&id=Item%20VI.%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital and information regarding its shareholders [Share Change Information](index=28&type=section&id=I.%20Share%20Change%20Information) During the reporting period, due to the implementation of the 2015 annual equity distribution plan of "10 bonus shares for every 10 shares", the company's total share capital increased from **640 million shares** to **1.28 billion shares**. Restricted and unrestricted shares increased proportionally Share Change Comparison | Share Type | Before This Change (Shares) | After This Change (Shares) | | :--- | :--- | :--- | | Restricted Shares | 233,712,572 | 466,441,142 | | Unrestricted Shares | 406,287,428 | 813,558,858 | | **Total Shares** | **640,000,000** | **1,280,000,000** | - The main reason for the share change was the implementation of the 2015 annual equity distribution plan: **10 bonus shares** for every **10 shares** from capital reserves[104](index=104&type=chunk) [Number of Shareholders and Shareholding Information](index=31&type=section&id=II.%20Number%20of%20Shareholders%20and%20Shareholding%20Information) As of the end of the reporting period, the company had a total of **54,793** common shareholders. The top two shareholders are company executives Wang Yaofang and Zhao Gang, holding **22.80%** and **11.40%** respectively, indicating a relatively concentrated equity structure - As of the end of the reporting period, the company had a total of **54,793** common shareholders[113](index=113&type=chunk) Top Ten Shareholders' Shareholding (As of End of Reporting Period) | Shareholder Name | Shareholder Nature | Shareholding Ratio | Number of Shares Held (Shares) | | :--- | :--- | :--- | :--- | | Wang Yaofang | Domestic Natural Person | 22.80% | 291,888,000 | | Zhao Gang | Domestic Natural Person | 11.40% | 145,944,000 | | Jiang Jianping | Domestic Natural Person | 3.80% | 48,648,000 | | Haitong Securities Co., Ltd. | State-owned Legal Person | 3.26% | 41,781,115 | | Industrial and Commercial Bank of China - GF Jufeng Mixed Securities Investment Fund | State-owned Legal Person | 2.70% | 34,500,000 | [Changes in Controlling Shareholder or Actual Controller](index=33&type=section&id=III.%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) During the reporting period, there were no changes in the company's controlling shareholder or actual controller - The company's controlling shareholder and actual controller did not change during the reporting period[116](index=116&type=chunk) [Information on Preferred Shares](index=34&type=section&id=Item%20VII.%20Information%20on%20Preferred%20Shares) This section confirms the absence of preferred shares in the company's capital structure during the reporting period - The company had no preferred shares during the reporting period[119](index=119&type=chunk) [Information on Directors, Supervisors, and Senior Management](index=35&type=section&id=Item%20VIII.%20Information%20on%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) This section provides details on the shareholding and changes of the company's directors, supervisors, and senior management [Shareholding Changes of Directors, Supervisors, and Senior Management](index=35&type=section&id=I.%20Shareholding%20Changes%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, the shareholdings of the company's directors, supervisors, and senior management increased proportionally due to the implementation of the capital reserve to share capital conversion plan of "10 bonus shares for every 10 shares", with the total number of shares held at period-end doubling compared to the beginning of the period - Shareholding changes of directors, supervisors, and senior management primarily resulted from the capital reserve to share capital conversion; the number of shares increased in this period equals the initial shareholding, doubling the total shares held at period-end[121](index=121&type=chunk) Major D&O Shareholding Changes (Shares) | Name | Position | Shares Held at Beginning of Period | Shares Increased in Current Period | Shares Held at End of Period | | :--- | :--- | :--- | :--- | :--- | | Wang Yaofang | Chairman | 145,944,000 | 145,944,000 | 291,888,000 | | Zhao Gang | Vice Chairman, General Manager | 72,972,000 | 72,972,000 | 145,944,000 | | Jiang Jianping | Chairman of Supervisory Board | 24,324,000 | 24,324,000 | 48,648,000 | [Changes in Directors, Supervisors, and Senior Management](index=36&type=section&id=II.%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, there were no changes in the company's directors, supervisors, and senior management - The company's directors, supervisors, and senior management did not change during the reporting period[122](index=122&type=chunk) [Financial Report](index=37&type=section&id=Item%20IX.%20Financial%20Report) This section presents the company's financial statements and related notes [Audit Report](index=37&type=section&id=I.%20Audit%20Report) The company's 2016 half-year financial report was not audited - The company's half-year financial report was not audited[125](index=125&type=chunk) [Financial Statements](index=37&type=section&id=II.%20Financial%20Statements) This section provides the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity as of June 30, 2016. The data shows total assets of **2.846 billion CNY**, net assets attributable to parent company of **2.321 billion CNY**, and net profit attributable to parent company of **143 million CNY** for the first half of the year [Consolidated Balance Sheet](index=37&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of June 30, 2016, the company's total assets were **2.846 billion CNY**, a slight increase of **0.44%** from the beginning of the period. Current assets totaled **2.06 billion CNY**, primarily consisting of other current assets (wealth management products) of **1.491 billion CNY**. Total liabilities were **502 million CNY**, and total owners' equity attributable to the parent company was **2.321 billion CNY** Consolidated Balance Sheet Key Items (CNY) | Item | Period-End Balance | Period-Beginning Balance | | :--- | :--- | :--- | | **Total Assets** | **2,845,714,250.45** | **2,833,137,726.31** | | Total Current Assets | 2,060,200,669.40 | 2,176,180,388.64 | | Total Non-Current Assets | 785,513,581.05 | 656,957,337.67 | | **Total Liabilities** | **502,243,855.11** | **538,670,103.54** | | **Total Owners' Equity Attributable to Parent Company** | **2,321,038,424.02** | **2,274,186,481.96** | [Consolidated Income Statement](index=42&type=section&id=3.%20Consolidated%20Income%20Statement) In the first half of 2016, the company achieved total operating revenue of **362 million CNY**, a year-on-year increase of **9.50%**. Operating profit was **169 million CNY**, an **8.3%** increase year-on-year. Net profit attributable to parent company owners was **143 million CNY**, a **7.29%** increase year-on-year Consolidated Income Statement Key Items (CNY) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | I. Total Operating Revenue | 362,339,737.55 | 330,909,032.54 | | II. Total Operating Costs | 193,504,569.78 | 175,109,085.64 | | III. Operating Profit | 168,846,970.88 | 155,898,288.25 | | IV. Total Profit | 169,097,825.64 | 158,105,886.63 | | Net Profit Attributable to Parent Company Owners | 142,851,942.06 | 133,143,671.57 | [Consolidated Cash Flow Statement](index=46&type=section&id=5.%20Consolidated%20Cash%20Flow%20Statement) In the first half of 2016, the company's net cash flow from operating activities was **161 million CNY**, a year-on-year decrease of **8.12%**. Net cash outflow from investing activities was **67 million CNY**, mainly due to the purchase of wealth management products. Net cash outflow from financing activities was **61 million CNY**, primarily for repaying bank loans. Cash and cash equivalents balance at period-end was **201 million CNY** Consolidated Cash Flow Statement Key Items (CNY) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 160,916,492.13 | 175,139,448.67 | | Net Cash Flow from Investing Activities | -66,846,282.54 | -218,372,770.22 | | Net Cash Flow from Financing Activities | -61,389,883.63 | 96,123,165.97 | | Net Increase in Cash and Cash Equivalents | 34,813,364.92 | 54,357,544.23 | [Notes to Consolidated Financial Statements](index=75&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statements) This chapter provides detailed explanations of key items in the consolidated financial statements. Key information includes: other current assets containing **1.491 billion CNY** in wealth management products; construction in progress primarily for fundraising projects, with a period-end balance of **522 million CNY**; goodwill of **10.57 million CNY** newly added due to the acquisition of Innosenkang; and financial expenses of negative **53.28 million CNY**, mainly benefiting from interest income from wealth management products - Other current assets at period-end amounted to **1.491 billion CNY**, of which **1.49 billion CNY** were wealth management products[293](index=293&type=chunk) - Construction in progress had a period-end book value of **522 million CNY**, primarily for five fundraising projects and one over-raised project, with a period-end balance of **514 million CNY**[331](index=331&type=chunk)[332](index=332&type=chunk) - Goodwill of **10,571,490.60 CNY** was newly added in this period due to the acquisition of Changzhou Innosenkang Biomedical Technology Co., Ltd.[345](index=345&type=chunk)[467](index=467&type=chunk) - Financial expenses were **-53,279,145.83 CNY**, mainly comprising interest income of **59,698,254.71 CNY** from wealth management products[433](index=433&type=chunk) [Changes in Consolidation Scope](index=116&type=section&id=VIII.%20Changes%20in%20Consolidation%20Scope) During the reporting period, the company added "Changzhou Innosenkang Biomedical Technology Co., Ltd." as a new consolidated entity due to a non-common control business combination. The company acquired **55%** of its equity for **16.5 million CNY** in cash on January 26, 2016, and this acquisition resulted in **10.57 million CNY** in goodwill - This period saw a non-common control business combination, with the acquisition of **55%** equity in Changzhou Innosenkang Biomedical Technology Co., Ltd. for **16.5 million CNY** in cash[466](index=466&type=chunk) Consolidation Cost and Goodwill (CNY) | Item | Amount | | :--- | :--- | | Total Consolidation Cost | 16,500,000.00 | | Less: Fair Value Share of Identifiable Net Assets Acquired | 5,928,509.40 | | **Goodwill** | **10,571,490.60** | [Interests in Other Entities](index=118&type=section&id=IX.%20Interests%20in%20Other%20Entities) This chapter discloses the company's enterprise group structure. As of the end of the reporting period, the company owned **7** subsidiaries, including Hubei Runhong (**100%** held), Jiangsu Zhonghong (**59%** held), and the newly acquired Innosenkang (**55%** held). Important non-wholly owned subsidiaries Jiangsu Zhonghong and Jiangsu Jinghong were both in a loss-making state during this period Enterprise Group Composition | Subsidiary Name | Shareholding Ratio (Direct) | Acquisition Method | | :--- | :--- | :--- | | Hubei Runhong Biotechnology Co., Ltd. | 100.00% | Establishment | | Jiangsu Zhonghong Bioengineering Innovation Research Institute Co., Ltd. | 59.00% | Establishment | | Jiangsu Jinghong Biomedical Technology Co., Ltd. | 51.00% | Establishment | | Changzhou Innosenkang Biomedical Technology Co., Ltd. | 55.00% | Non-common control business combination | [Supplementary Information](index=136&type=section&id=XVIII.%20Supplementary%20Information) This chapter provides supplementary financial information, including details of non-recurring gains and losses and return on net assets. During the reporting period, the company's total non-recurring gains and losses amounted to **47.42 million CNY**, primarily from wealth management product income. The weighted average return on net assets attributable to common shareholders was **6.13%**, and basic earnings per share was **0.1116 CNY/share** - Current period non-recurring gains and losses totaled **47,423,210.56 CNY**, with the main item being "other gains and losses items conforming to the definition of non-recurring gains and losses" (primarily wealth management income), amounting to **55,959,790.90 CNY**[556](index=556&type=chunk) Return on Net Assets and Earnings Per Share | Profit for the Period | Weighted Average Return on Net Assets | Basic Earnings Per Share (CNY/share) | Diluted Earnings Per Share (CNY/share) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Common Shareholders | 6.13% | 0.1116 | 0.1116 | | Net Profit Attributable to Common Shareholders (Excluding Non-recurring Gains/Losses) | 4.10% | 0.0746 | 0.0746 | [Reference Documents](index=138&type=section&id=Item%20X.%20Reference%20Documents) This section lists the official documents available for public inspection and verification of the report's contents - Reference documents include:<br>- Signed and sealed financial statements<br>- Original copies of all publicly disclosed documents and announcements during the reporting period<br>- Original text of the 2016 half-year report signed by the chairman[559](index=559&type=chunk)

[Important Notice](index=2&type=section&id=第一节%20重要提示) The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report - Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, with no false records, misleading statements, or major omissions, and assume legal responsibility[4](index=4&type=chunk) - All directors attended the board meeting to review this quarterly report[5](index=5&type=chunk) - The company's responsible person, the person in charge of accounting work, and the head of the accounting department declare to guarantee the truthfulness, accuracy, and completeness of the financial statements in the quarterly report[5](index=5&type=chunk) [Key Financial Data and Shareholder Changes](index=3&type=section&id=第二节%20主要财务数据及股东变化) Q1 2016 operating revenue slightly decreased, while net profit and EPS significantly increased, with stable operating cash flow and growing assets [Key Accounting Data and Financial Indicators](index=3&type=section&id=一、主要会计数据和财务指标) Q1 2016 operating revenue slightly decreased, while net profit attributable to shareholders and basic EPS significantly increased, with stable operating cash flow and growing assets Key Financial Indicators | Indicator | Current Period (Yuan) | Prior Year (Yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 156,701,933.57 | 163,844,266.85 | -4.36 | | Net Profit Attributable to Shareholders of the Listed Company | 70,245,573.36 | 60,704,275.85 | 15.72 | | Net Profit Attributable to Shareholders of the Listed Company (Excluding Non-recurring Gains and Losses) | 41,843,469.96 | 39,394,500.60 | 6.22 | | Net Cash Flow from Operating Activities | 77,933,315.15 | 72,874,161.51 | 6.94 | | Basic Earnings Per Share (Yuan/share) | 0.1098 | 0.0949 | 15.70 | | Diluted Earnings Per Share (Yuan/share) | 0.1098 | 0.0949 | 15.70 | | Weighted Average Return on Net Assets | 3.04 | 2.85 | 0.19 | Balance Sheet Indicators | Indicator | End of Current Period (Yuan) | End of Prior Year (Yuan) | Change from Prior Year End (%) | | :--- | :--- | :--- | :--- | | Total Assets | 2,882,358,315.91 | 2,833,137,726.31 | 1.74 | | Net Assets Attributable to Shareholders of the Listed Company | 2,344,432,055.32 | 2,274,186,481.96 | 3.09 | - Non-recurring gains and losses primarily include government subsidies (**5,327,100.00 yuan**) and investment income from bank wealth management products and trust products (**28,491,927.49 yuan**), positively impacting current net profit[9](index=9&type=chunk) [Total Number of Shareholders and Top Ten Shareholders' Holdings at the End of the Reporting Period](index=4&type=section&id=二、报告期末股东总数及前十名股东持股情况表) As of the end of the reporting period, the company had 47,633 common shareholders, with significant stakes held by natural persons and major institutional investors - The total number of common shareholders at the end of the reporting period was **47,633**, with no preferred shareholders whose voting rights have been restored[12](index=12&type=chunk) Top Ten Common Shareholders' Holdings | Shareholder Name | Shareholder Nature | Holding Percentage (%) | Number of Shares Held (Shares) | Number of Restricted Shares Held (Shares) | | :--- | :--- | :--- | :--- | :--- | | Wang Yaofang | Domestic Natural Person | 22.80 | 145,944,000 | 115,200,000 | | Zhao Gang | Domestic Natural Person | 11.40 | 72,972,000 | 54,729,000 | | Jiang Jianping | Domestic Natural Person | 3.80 | 24,324,000 | 18,243,000 | | Industrial and Commercial Bank of China - GF Jufeng Mixed Securities Investment Fund | State-owned Legal Person | 2.79 | 17,879,047 | 0 | | Haitong Securities Co., Ltd. | State-owned Legal Person | 2.64 | 16,890,082 | 0 | - The company's top 10 common shareholders and top 10 unrestricted common shareholders did not engage in agreed repurchase transactions during the reporting period[13](index=13&type=chunk) [Significant Events](index=6&type=section&id=第三节%20重要事项) Significant changes in key financial items and indicators were driven by increased wealth management, asset sales, bonus payments, and government subsidies [Changes and Reasons for Key Financial Statement Items and Indicators](index=6&type=section&id=一、报告期主要会计报表项目、财务指标发生变动的情况及原因) Key financial items and indicators changed significantly due to increased wealth management, asset sales, bonus payments, government subsidies, and bank borrowings - Cash and cash equivalents at the end of the reporting period decreased by **79.23%** compared to the beginning of the period, mainly due to increased wealth management investments[16](index=16&type=chunk) - Net cash flow from investment activities decreased by **284.611 million yuan** compared to the same period last year, primarily due to increased wealth management investments during the reporting period[17](index=17&type=chunk) - Non-operating income increased by **4.9844 million yuan** compared to the same period last year, mainly due to an increase in government subsidies received during the current period[17](index=17&type=chunk) - Employee compensation payable at the end of the reporting period decreased by **57.85%** compared to the beginning of the period, mainly due to the payment of accrued 2015 annual bonuses[16](index=16&type=chunk) [Progress of Significant Events](index=6&type=section&id=二、重要事项进展情况及其影响和解决方案的分析说明) Significant progress was made in drug registration, production licenses, and external investments, including new approvals, GMP certificates, and acquisition completion - In January 2016, the company obtained drug registration approvals for **Dalteparin Sodium and its injection**[18](index=18&type=chunk) - In February 2016, the company obtained a **GMP certificate for Enoxaparin Sodium API**[18](index=18&type=chunk) - In February 2016, the acquisition of **Changzhou Innoshine Bio-Pharmaceutical Technology Co., Ltd.** completed its industrial and commercial change registration[18](index=18&type=chunk) [Fulfillment of Commitments](index=7&type=section&id=三、公司、股东、实际控制人、收购人、董事、监事、高级管理人员或其他关联方在报告期内履行完毕及截至报告期末尚未履行完毕的承诺事项) Major shareholders and management strictly fulfilled IPO/refinancing commitments on competition, related party transactions, fund occupation, and share lock-ups - Controlling shareholders and actual controllers committed not to engage in any business or activities that constitute horizontal competition with the company, and this commitment is being strictly fulfilled[20](index=20&type=chunk) - Major shareholders committed to an additional **3-year lock-up period** for company shares, from February 25, 2014, to February 24, 2017, which is currently being fulfilled normally[21](index=21&type=chunk) - Controlling shareholders, actual controllers, shareholders holding **5% or more** of shares, and directors, supervisors, and senior management committed not to reduce their holdings through the secondary market for **6 months** from July 10, 2015, which has been fulfilled as of the disclosure date of this report[22](index=22&type=chunk) [2016 H1 Performance Forecast](index=9&type=section&id=四、对%202016%20年%201-6%20月经营业绩的预计) H1 2016 net profit attributable to shareholders is forecast to increase by **0% to 20%**, driven by sales costs and prices Forecast for Net Profit Attributable to Shareholders | Indicator | Change Range (%) | Change Interval (Million Yuan) | Net Profit Attributable to Shareholders H1 2015 (Million Yuan) | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of the Listed Company | 0.00 to 20.00 | 133.1437 to 159.7724 | 133.1437 | - The main reasons for the performance change are **sales costs and sales price factors**[23](index=23&type=chunk) [Financial Assets Measured at Fair Value](index=10&type=section&id=五、以公允价值计量的金融资产) Financial assets measured at fair value, primarily fund investments, were sold during the period, realizing a cumulative investment income of **255,697.57 yuan** Financial Assets Measured at Fair Value | Asset Category | Initial Investment Cost (Yuan) | Fair Value Change Gain/Loss for the Period (Yuan) | Amount Sold During the Period (Yuan) | Cumulative Investment Income (Yuan) | Source of Funds | | :--- | :--- | :--- | :--- | :--- | :--- | | Funds | 10,000,000.00 | -246,694.46 | 10,255,697.57 | 255,697.57 | Own Funds | [Illegal External Guarantees](index=10&type=section&id=六、违规对外担保情况) The company had no illegal external guarantees during the reporting period - The company had no illegal external guarantees during the reporting period[26](index=26&type=chunk) [Occupation of Funds by Controlling Shareholders and Related Parties](index=10&type=section&id=七、控股股东及其关联方对上市公司的非经营性占用资金情况) During the reporting period, there was no non-operating occupation of listed company funds by controlling shareholders or their related parties - During the reporting period, there was no non-operating occupation of listed company funds by controlling shareholders or their related parties[27](index=27&type=chunk) [Survey and Reception Activities](index=10&type=section&id=八、报告期内接待调研、沟通、采访等活动登记表) During the reporting period, the company hosted one institutional on-site survey on January 12, 2016 - On January 12, 2016, the company hosted an institutional on-site survey, details of which can be found on Juchao Information Network in the "Institutional Survey Record on January 12, 2016"[28](index=28&type=chunk)

常州千红生化制药股份有限公司 2015 年年度报告全文 常州千红生化制药股份有限公司 2015 年年度报告 | 股票简称：千红制药 | | --- | | 股票代码： 002550 | 2016 年 04 月 26 日 1 常 常州千红生化制药股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人王耀方、主管会计工作负责人金小东及会计机构负责人(会计主 管人员)金小东声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能存在药品招标风险，外部经济环境的不确定性风险、产品质量风 险、产品销售价格波动的风险、经营成本增加的风险、行业竞争加剧的风险、 汇率波动的风险等。 公司经本次董事会审议通过的利润分配预案为：以 640000000 为基数，向 全体股东每 10 股派发现金红利 1.5 元（含税），送红股 0 股（含税），以资本公 积金向全体股东每 10 股转增 10 股。 2 | 第一节 ...

Financial Performance - Net profit attributable to shareholders decreased by 2.91% to CNY 68,187,040.20 for the reporting period[9] - Operating revenue decreased by 7.00% to CNY 191,490,982.21 for the reporting period[9] - Basic earnings per share decreased by 9.09% to CNY 0.10 for the reporting period[9] - The estimated net profit attributable to shareholders of the listed company for 2015 is expected to increase by 5% to 20%, ranging from 257.29 million to 294.04 million yuan[22] Assets and Liabilities - Total assets increased by 13.91% to CNY 2,632,202,667.94 compared to the end of the previous year[9] - Prepayments increased by 123.49% compared to the beginning of the period, mainly due to increased advance payments[16] - Construction in progress increased by 62.31% compared to the beginning of the period, attributed to increased investment in ongoing projects[16] - Accounts payable decreased by 85.10% compared to the beginning of the period, primarily due to payments made for outstanding goods[16] - Other current liabilities decreased by 94.11% compared to the beginning of the period, mainly due to a reduction in unpaid market development expenses[17] - Long-term borrowings decreased by 27 million yuan compared to the beginning of the period, primarily due to a decrease in unpaid bank loans over one year[17] - Short-term borrowings increased by 280 million yuan compared to the beginning of the period, mainly due to an increase in bank loans[17] - Deferred income increased by 197.87% compared to the beginning of the period, mainly due to receiving infrastructure subsidy payments[17] Cash Flow - Cash flow from operating activities increased by 22.17% to CNY 271,782,897.13 year-to-date[9] - Net cash flow from financing activities increased by 420.07% compared to the same period last year, mainly due to an increase in bank loans[18] Operating Costs and Income - Operating costs decreased by 36.84% compared to the same period last year, primarily due to a decrease in the purchase price of heparin sodium crude products[17] - Asset impairment losses increased by 82.49% compared to the same period last year, mainly due to a decrease in inventory impairment write-offs[17] - Investment income increased by 344,100 yuan compared to the same period last year, mainly due to increased income from the sale of Minsheng Jia Yin money market funds[17] - The decrease in operating income from non-operating activities was 44.83% compared to the same period last year, mainly due to a reduction in government subsidies[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,230[12] - The largest shareholder, Wang Yaofang, holds 22.80% of the shares, totaling 145,944,000 shares[12]

常州千红生化制药股份有限公司 2015 年半年度报告全文 常州千红生化制药股份有限公司 2015 年半年度报告 股票简称：千红制药 股票代码：002550 2015 年 08 月 1 常州千红生化制药股份有限公司 2015 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人王耀方、主管会计工作负责人金小东及会计机构负责人(会计主 管人员)金小东声明：保证本半年度报告中财务报告的真实、准确、完整。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 5 | | --- | --- | | 第二节 | 公司简介 7 | | 第三节 | 会计数据和财务指标摘要 9 | | 第四节 | 董事会报告 23 | | 第五节 | 重要事项 28 | | 第六节 | 股份变动及股东情况 32 | | 第七节 | 优先股相关情况 32 | | 第八节 ...

常州千红生化制药股份有限公司 2015 年第一季度报告正文 证券代码：002550 证券简称：千红制药 公告编号：2015-023 常州千红生化制药股份有限公司 2015 年第一季度报告正文 证券简称：千红制药 证券代码：002550 2015 年 04 月 25 日 1 常州千红生化制药股份有限公司 2015 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王耀方、主管会计工作负责人金小东及会计机构负责人(会计主 管人员)金小东声明：保证季度报告中财务报表的真实、准确、完整。 2 常州千红生化制药股份有限公司 2015 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 √ 是 □ 否 | | 本报告期 | 上年同期 | | 本报告期比上年同 | | --- | --- | --- | --- | --- | | ...

常州千红生化制药股份有限公司 2014 年年度报告全文 常州千红生化制药股份有限公司 2014 年年度报告 股票简称：千红制药 股票代码： 002550 2015 年 04 月 25 日 1 常州千红生化制药股份有限公司 2014 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司经本次董事会审议通过的利润分配预案为：以 320000000 为基数，向 全体股东每 10 股派发现金红利 3.00 元（含税），送红股 0 股（含税），以资本公 积金向全体股东每 10 股转增 10 股。 公司负责人王耀方、主管会计工作负责人金小东及会计机构负责人(会计主 管人员)金小东声明：保证年度报告中财务报告的真实、准确、完整。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介 6 | | 第三节 | 会计数据和财务指标摘要 8 | | 第四节 | 董事会报告 10 | | 第 ...